As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap, worth over $300 billion annually, between a drug’s inflated list price ...

Explore how PBMs negotiate drug costs, serve as middlemen between insurers and drug makers, and why they're vital yet controversial in healthcare.

The conclusion of the longest government shutdown in history and rising political acrimony rightly receives a great deal of attention but this focus makes it easy to overlook areas where beneficial ...